This is a non-randomized, non-interventional pilot observational study designed to follow high-risk patients through their surgical and hospital stay. The investigators will collect 2 4ml vial's of blood (total of 8ml) prior to surgery to assess CV biomarkers - inflammatory, metabolic, hypercoagulable and platelet.
This study is primarily an observational pilot study. After identifying patients as high-risk according to the following criteria: CAD and/or CVD and/or PAD and/or \>=60 years old and at least 2 of the following - renal insufficiency, diabetes, COPD, hypertension, active smoker (or active within 6 months of consent), cancer, congestive heart failure, or any blood clot - they will be asked to sign a consent form. Patients surgical and hospital course will continue as per standard of care. Prior to surgery, 8ml of blood will be collected for to assess cardiovascular biomarkers including inflammatory, metabolic, hypercoagulable and platelet biomarkers to be tested independently in Dr. Berger's lab in Smilow. Study staff will perform electrocardiograms on POD 2. Results of these ECGs will not be placed in the patients' charts. No other procedures will be done for research purposes only.
Study Type
OBSERVATIONAL
NYU Hospital for Joint Diseases
New York, New York, United States
Cardiac ischemia/necrosis
Time frame: 30 days
Venous thromboembolism
Time frame: 30 days
Pulmonary embolism
Time frame: 30 dyas
Myocardial infarction
Time frame: 30 Days
Cerebral vascular event
Time frame: 30 days
Death
Time frame: 30 days
Transient ischemic attack
Time frame: 30 days
Surgical site infection
Time frame: 30 days
Delayed wound healing
Time frame: 30 days
Clinically relevant bleeding
Time frame: 30 days
Transfusion within 48 hours post-op
Time frame: 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.